Clinical trials
Withdrawn trials in Mexico
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
86 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 9 |
| 2007 | 3 |
| 2008 | 9 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 8 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 4 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 7 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 86 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Asociación para Evitar la Ceguera en México | 20 |
| Ageless Regenerative Institute | 6 |
| Bristol-Myers Squibb | 6 |
| Instituto Nacional de Salud Publica, Mexico | 3 |
| Takeda | 3 |
| Coordinación de Investigación en Salud, Mexico | 2 |
| Grupo Cooperativo de Hemopatías Malignas | 2 |
| Hospital Universitario Dr. Jose E. Gonzalez | 2 |
| Laboratorios Sophia S.A de C.V. | 2 |
| National Institute of Medical Sciences and Nutrition, Salvador Zubiran | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 5 |
| Diabetes Mellitus, Type 2 | 5 |
| Diabetic Retinopathy | 3 |
| Macular Edema | 3 |
| Obesity | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Diarrhea | 2 |
| Heart Failure | 2 |
| Uterine Cervical Neoplasms | 2 |
| Uveitis | 2 |
Trials
Showing 26 to 50 of 86. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.